Prognostic role of TP53 variants in the phase III study of FOLFIRI/cetuximab versus FOLFIRI/cetuximab followed by cetuximab (Cet) alone in first-line therapy of patients with RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC) (ERMES study)

被引：0
|
作者：
Normanno, Nicola
Orlandi, Armando
Maiello, Evaristo
Rachiglio, Anna Maria
Maglietta, Giuseppe
Damato, Angela
Calegari, Maria Alessandra
Antonuzzo, Lorenzo
Bordonaro, Roberto
Zampino, Maria Giulia
Tamberi, Stefano
Lonardi, Sara
Tonini, Giuseppe
Rosati, Gerardo
Latiano, Tiziana Pia
Tamburini, Emiliano
Maiello, Monica Rosaria
Carotenuto, Marianeve
Barone, Carlo
Pinto, Carmine
机构：
[1] Ist Nazl Tumori IRCCS Fdn Pascale, Cell Biol & Biotherapy Unit, Naples, Italy
[2] Fdn Policlin Univ A Gemelli IRCCS, UOC Oncol Med, Rome, Italy
[3] Casa Sollievo Sofferenza, San Giovanni Rotondo, Italy
[4] Ist Nazl Tumori IRCCS Fdn G Pascale, Cell Biol & Biotherapy Unit, Naples, Italy
[5] Univ Hosp Parma, Clin & Epidemiol Res Unit, Parma, Italy
[6] AUSL IRCCS Reggio Emilia, Comprehens Canc Center, Med Oncol Unit, Reggio Emilia, Italy
[7] Fdn Policlin Univ Agostino Gemelli IRCCS, Ctr Comprehens Canc, Oncol Med, Rome, Italy
[8] Careggi Univ Hosp, Dept Expt & Clin Med, Clin Oncol Unit, Florence, Italy
[9] Azienda Osped ARNAS Garibaldi, Med Oncol, Catania, CT, Italy
[10] Ist Europeo Oncol IRCCS, Med Oncol Deparment, Milan, Italy
[11] Santa Maria Croci Hosp, Oncol Unit, Ravenna, Italy
[12] Veneto Inst Oncol IOV IRCCS, Dept Oncol, Padua, Italy
[13] Univ Campus Biomed, Dept Med Oncol, Rome, Italy
[14] Azienda Osped S Carlo, Potenza, Italy
[15] Fdn IRCCS Casa Sollievo Sofferenza, Oncol Unit, San Giovanni Rotondo, Italy
[16] Tricase City Hosp, Dept Oncol, Tricase, Italy
[17] Policlin Univ Agostino Gemelli, UOC Oncol Med, Rome, Italy
[18] AUSL IRCCS, Med Oncol Unit, Ctr Comprehens Canc, Reggio Emilia, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3544
引用
收藏
页数：1
相关论文
共 50 条
  • [21] COMPARISON OF FOLFOX6 PLUS CETUXIMAB WITH FOLFIRI PLUS CETUXIMAB AS FIRST-LINE THERAPY IN METASTATIC COLORECTAL CANCER (MCRC): A RANDOMIZED OPEN-LABEL PHASE II CECOG STUDY
    Beslija, S.
    Koza, I.
    Ocvirk, J.
    Ciuleanu, T.
    Kurteva, G.
    Papamichael, D.
    Vrbanec, D.
    Messinger, D.
    Brodowicz, T.
    Zielinski, C. C.
    ANNALS OF ONCOLOGY, 2008, 19 : 168 - 168
  • [22] Cost-Effectiveness Analysis of First-Line FOLFIRI Combined With Cetuximab or Bevacizumab in Patients With RAS Wild-Type Left-Sided Metastatic Colorectal Cancer
    Han, Jiaqi
    Xiao, Desheng
    Tan, Chongqing
    Zeng, Xiaohui
    Hu, Huabin
    Zeng, Shan
    Jiang, Qin
    She, Longjiang
    Yao, Linli
    Li, Li
    Tang, Lanhua
    Ma, Jian
    Huang, Jin
    Shen, Liangfang
    CANCER CONTROL, 2020, 27 (01)
  • [23] Prognostic factors in KRAS wild-type (wt) metastatic colorectal cancer (mCRC) patients (pts) treated with biweekly cetuximab (C) plus irinotecan, fluorouracil, and leucovorin (FOLFIRI): A phase II study
    Personeni, Nicola
    Rimassa, Lorenza
    Verusio, Claudio
    Barni, Sandro
    Destro, Annarita
    Raschioni, Carlotta
    Armenia, Silvia
    Floriani, Irene
    Gerardi, Chiara
    Monteforte, Marta
    Villa, Eugenio
    Bozzarelli, Silvia
    Roncalli, Massimo
    Torri, Valter
    Labianca, Roberto
    Santoro, Armando
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [24] Early tumor shrinkage (ETS) as clinical factor to select maintenance with cetuximab (cet) monotherapy in patients (pts) with RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC): A secondary endpoint analysis of the ERMES study
    Orlandi, Armando
    Pinto, Carmine
    Calegari, Maria Alessandra
    Normanno, Nicola
    Maiello, Evaristo
    Antonuzzo, Lorenzo
    Bordonaro, Roberto
    Zampino, M. Giulia
    Bergamo, Francesca
    Tonini, Giuseppe
    Tamberi, Stefano
    Avallone, Antonio
    Latiano, Tiziana Pia
    Rosati, Gerardo
    Pazzola, Antonio
    Ballestrero, Alberto
    Zaniboni, Alberto
    Formica, Vincenzo
    Barone, Carlo
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [25] A COST-EFFECTIVENESS ANALYSIS (CEA) OF CETUXIMAB plus FOLFIRI COMPARED TO BEVACIZUMAB plus FOLFIRI AS FIRST-LINE TREATMENT OF RAS WILD-TYPE (WT) METASTATIC COLORECTAL CANCER (MCRC): A US ANALYSIS BASED ON LOCATION OF PRIMARY TUMOR
    Evans, R.
    Aggarwal, H.
    Takundwa, R.
    Chin, S.
    Fenwick, E.
    VALUE IN HEALTH, 2018, 21 : S31 - S31
  • [26] Multicenter phase II study of FOLFOX or biweekly XELOX and cetuximab as first-line treatment in patients with wild-type KRAS/BRAF metastatic colorectal cancer (mCRC) (FLEET study)
    Kim, Ho Min
    Soda, Hitoshi
    Hazama, Shoichi
    Takahashi, Takao
    Nagata, Naoki
    Kotaka, Masahito
    Kono, Emiko
    Terada, Itsurou
    Fukunaga, Mutsumi
    Oba, Koji
    Hasegawa, Junichi
    Sakamoto, Junichi
    Mishima, Hideyuki
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [27] Phase II APEC trial: The impact of primary tumor side on outcomes of first-line cetuximab plus FOLFOX or FOLFIRI in patients with RAS wild-type metastatic colorectal cancer
    Price, Timothy
    Shen, Lin
    Ma, Brigette
    Esser, Regina
    Chen, Wenfeng
    Gibbs, Peter
    Lim, Robert
    Cheng, Ann-Lii
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2019, 15 (04) : 225 - 230
  • [28] First-line cetuximab versus bevacizumab for RAS and BRAF wild-type metastatic colorectal cancer: a systematic review and meta-analysis
    Bobo Zheng
    Xin Wang
    Mingtian Wei
    Quan Wang
    Jiang Li
    Liang Bi
    Xiangbing Deng
    Ziqiang Wang
    BMC Cancer, 19
  • [29] First-line cetuximab versus bevacizumab for RAS and BRAF wild-type metastatic colorectal cancer: a systematic review and meta-analysis
    Zheng, Bobo
    Wang, Xin
    Wei, Mingtian
    Wang, Quan
    Li, Jiang
    Bi, Liang
    Deng, Xiangbing
    Wang, Ziqiang
    BMC CANCER, 2019, 19 (1)
  • [30] A randomized, open-label CECOG phase II study evaluating the efficacy and safety of FOLFOX6+cetuximab versus FOLFIRI plus cetuximab as first-line therapy in patients (pts) with metastatic colorectal cancer (mCRC)
    Ciuleanu, T. E.
    Kurteva, G.
    Ocvirk, J.
    Beslija, S.
    Koza, I.
    Papamichael, D.
    Vrbanec, D.
    Brodowicz, T.
    Scheithauer, W.
    Zielinski, C. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345